SCHEMBL9924151

SCHEMBL9924151

O=C(/N=C(/NCc1ccc(Cl)cc1F)N[C@H]1CC[C@H](Nc2ncccn2)CC1)c1ccc(F)c(F)c1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.48
P2RX7 Q99572 7/20 0.45
MCHR1 Q99705 8/20 0.42
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
ADRA1A P35348 1/20 0.39
HRH1 P35367 1/20 0.39
HTR2B P41595 1/20 0.39
NPY5R Q15761 1/20 0.39
VNN1 O95497 1/20 0.38
PDE4B Q07343 2/20 0.37
PDE4D Q08499 1/20 0.37
ROCK2 O75116 1/20 0.37
ROCK1 Q13464 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9924245 0.90 EPHX2 (0.49) EPHX2P2RX7MCHR1
SCHEMBL9924235 0.90 EPHX2 (0.46) EPHX2MCHR1HTR1AADRA2AADRA1A
SCHEMBL9924234 0.90 EPHX2 (0.41) EPHX2P2RX7MCHR1HTR1AADRA2A
SCHEMBL9924272 0.86 P2RX7 (0.41) P2RX7MCHR1HTR2BROCK2ROCK1
SCHEMBL9924253 0.86 MAPK1 (0.43) EPHX2P2RX7MCHR1HTR1AADRA2A
SCHEMBL9924246 0.85 P2RX7 (0.43) EPHX2P2RX7MCHR1HTR1AADRA2A
SCHEMBL17206715 0.85 EPHX2 (0.42) EPHX2P2RX7MCHR1HTR1AADRA2A
SCHEMBL17206701 0.82 MCHR1 (0.44) EPHX2MCHR1HTR1AADRA2AADRA1A
SCHEMBL9924064 0.82 CHRM1 (0.40) P2RX7MCHR1ROCK2ROCK1
SCHEMBL9924073 0.81 MCHR1 (0.46) MCHR1HTR1AADRA2AADRA1AHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed